The next-generation sequencing (NGS) market is gaining momentum as healthcare providers, pharmaceutical companies, and research institutions increasingly use genomic technologies to understand diseases and develop personalized treatments. Advances in precision medicine, cancer research, genetic testing, and molecular diagnostics are expanding the role of NGS across clinical and research settings. Improvements in sequencing accuracy, throughput, automation, and bioinformatics are also making genomic analysis more accessible. As the cost of sequencing declines and the demand for faster, comprehensive genetic insights increases, NGS is becoming an important technology in modern healthcare and life sciences.
Market Overview and Key Facts
The global next-generation sequencing market was valued at USD 11.3 billion in 2025. It is estimated to reach USD 13.3 billion in 2026 and is projected to reach USD 42.2 billion by 2033, registering a compound annual growth rate (CAGR) of 18.0% from 2026 to 2033. North America dominated the global market in 2025, accounting for 44.8% of revenue.
Key market facts include:
- Market Size (2025): USD 11.3 billion
- Estimated Market Size (2026): USD 13.3 billion
- Projected Market Size (2033): USD 42.2 billion
- Market CAGR:0% from 2026 to 2033
- Dominant Region: North America, with 44.8% revenue share in 2025
- Leading Technology: Targeted sequencing and resequencing, with 48.3% share in 2025
- Leading Application: Oncology, with approximately 32.0% share in 2025
- Leading Workflow: Sequencing, with 64.3% revenue share in 2025
- Leading End Use: Academic research, with 36.0% revenue share in 2025
- Fastest-Growing Region: Asia Pacific
The market is benefiting from the growing use of genomic information in disease diagnosis, drug discovery, clinical research, and population health initiatives. Increasing investments in biotechnology and precision medicine are further supporting demand for NGS platforms, consumables, and data analysis solutions.
Market Segmentation and Growth Dynamics
By technology, targeted sequencing and resequencing held the largest revenue share in 2025. These methods focus on selected genomic regions and help researchers identify mutations, genetic variations, and disease-associated biomarkers. Whole genome sequencing and whole exome sequencing are also gaining adoption as healthcare and research organizations seek broader genomic information. Whole exome sequencing is expected to record strong growth during the forecast period.
By product, the market includes sequencing platforms and consumables. Consumables represent an important category because sequencing workflows require reagents, sample preparation materials, target enrichment products, and other recurring supplies. The consumables segment is expected to grow at the fastest rate through 2033, supported by increasing sequencing volumes across research and clinical laboratories.
By application, oncology represented the largest segment in 2025, accounting for approximately 32.0% of market revenue. NGS supports cancer research, tumor profiling, companion diagnostics, inherited cancer screening, and the identification of genetic alterations that may influence treatment selection. Clinical investigation is another important application, covering infectious, inherited, and other diseases. Consumer genomics is expected to experience strong growth as individuals show greater interest in ancestry analysis and personal genetic information.
By workflow, sequencing accounted for 64.3% of revenue in 2025. NGS data analysis is also becoming increasingly important as laboratories manage large volumes of genomic information. By end use, academic research held the largest share, while clinical research is expected to grow rapidly due to increasing use of NGS in oncology studies, biomarker discovery, and precision medicine development.
Go Deeper! Ask Prism AI
about the Global Next Generation Sequencing Market. Get instant answers to questions related to market sizing, growth drivers & their impact, and more.
Regional Insights
North America dominated the global next-generation sequencing market with a 44.8% revenue share in 2025. The region benefits from advanced healthcare infrastructure, strong biotechnology research capabilities, high research and development spending, and the presence of leading sequencing companies. The U.S. is a major contributor, supported by genomic medicine initiatives and growing adoption of NGS in clinical laboratories, hospitals, and research institutions.
Asia Pacific is expected to register the fastest growth during the forecast period, with a projected CAGR of 18.43%. Increasing healthcare expenditure, expanding genomic research infrastructure, and rising adoption of precision medicine are supporting regional demand. China, Japan, India, and South Korea are investing in biotechnology, genetic testing, and clinical genomics. Growing public-private partnerships and local biotechnology companies are also strengthening the regional market.
Europe represents a significant market due to government support for genomic research, established healthcare systems, and increasing clinical applications of NGS. Germany, the UK, and France are important contributors, particularly in cancer genomics, rare disease diagnostics, and pharmaceutical research.
The Middle East and Africa market is developing as countries such as Saudi Arabia, the UAE, and Kuwait invest in healthcare modernization, genomic research, and personalized medicine. Latin America also offers opportunities through expanding molecular diagnostics and biotechnology capabilities.
Competitive Landscape
The NGS market includes established sequencing technology developers, biotechnology companies, diagnostic solution providers, and genomic data analysis specialists. Major industry participants include:
- Illumina, Inc.
- Hoffmann-La Roche Ltd.
- QIAGEN N.V.
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies plc
- Revvity, Inc.
- Merck KGaA
- BGI Genomics
Companies are focusing on improving sequencing speed, accuracy, scalability, and affordability. Investments in bioinformatics, cloud-based genomic analysis, automation, and clinical applications are also shaping competition. Strategic collaborations, product launches, and technology acquisitions are helping companies expand their portfolios and strengthen their global presence.
Looking for more specific insights? Customize this report to suite your business needs
About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.